Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation
Breakthrough in Cancer Treatment: Silexion Therapeutics announced significant preclinical results for its RNAi therapy SIL204, achieving up to 97% inhibition in pancreatic cancer cells and nearly 90% in colorectal cancer cells, including efficacy against the KRAS Q61H mutation.
Future Clinical Trials: The company plans to initiate a Phase 2/3 clinical trial in Q2 2026 to further investigate SIL204's potential in treating KRAS-driven solid tumors, building on its promising preclinical findings across multiple cancer types.
Trade with 70% Backtested Accuracy
Analyst Views on SLXN
About SLXN
About the author
Silexion Finishes Toxicology Studies for SIL204; Phase 2/3 Trial for Pancreatic Cancer Set to Start in Q2
SIL204 Development: Silexion Therapeutics has completed toxicology studies for SIL204, a next-generation siRNA therapy targeting mutated KRAS oncogenes in pancreatic cancer, showing no systemic organ toxicity.
Therapeutic Potential: SIL204 has demonstrated significant inhibition of cancer cell growth in preclinical models and positive anti-tumor activity in pancreatic cancer, paving the way for regulatory submissions in Israel and Germany.
Clinical Trial Plans: The therapy is set to progress to a Phase 2/3 trial in Q2 2026, utilizing a unique regimen that combines intratumoral and systemic administration to evaluate safety and efficacy in patients with locally advanced pancreatic cancer.
Stock Performance: Silexion's stock has fluctuated between $2.13 and $63.45 over the past year, closing at $2.44, reflecting a 13.48% increase in recent trading.
Silexion Completes Toxicology Studies for SIL204, Plans Phase 2/3 Trial in 2026
- Successful Toxicology Studies: Silexion has completed dual-species toxicology studies for SIL204, confirming no systemic organ toxicity, which lays the groundwork for planned regulatory submissions in Israel and Germany, potentially accelerating clinical trial progress.
- Clinical Trial Timeline: The company is on track to initiate a Phase 2/3 clinical trial for locally advanced pancreatic cancer in Q2 2026, ensuring competitiveness and timely market entry in the oncology sector.
- Innovative Therapy Potential: SIL204, designed as a next-generation RNA interference therapy targeting mutant KRAS oncogenes, has demonstrated significant anti-tumor activity in vitro, indicating its substantial potential in treating aggressive cancers.
- Integrated Treatment Strategy: The company's approach combines both intratumoral and systemic administration, aiming to improve survival rates for patients suffering from high-mortality cancers that currently lack effective treatment options.
Silexion Therapeutics Meets Nasdaq Listing Standards Again
Regaining Compliance: Silexion Therapeutics has regained compliance with Nasdaq listing rules regarding minimum bid price and shareholders' equity, confirming a minimum bid price of $1.00 per share and $2.5 million in shareholders' equity.
Clinical Development Focus: The company is advancing towards Phase 2/3 clinical trials for its RNAi therapy SIL204, which has shown promising preclinical results in inhibiting KRAS-driven cancers, and is committed to developing innovative treatments for solid tumor cancers.
Silexion Therapeutics Stock Rises Following Encouraging Preclinical Results for Pancreatic Cancer
Stock Performance: Silexion Therapeutics Corp. (SLXN) stock rose 14.83% to $5.15 on Thursday, with a trading volume significantly higher than its average, following the release of promising preclinical data.
Preclinical Study Findings: New data shows that SIL204 effectively targets pancreatic cancer metastasis, demonstrating anti-tumor activity and significant reductions in tumor burden across multiple organs in a mouse model, supporting its potential for clinical trials.
What’s Behind the 190% Surge in Silexion Therapeutics Stock (SLXN) Today?
Stock Performance: Silexion Therapeutics (SLXN) stock surged 188.07% in pre-market trading after positive pre-clinical data for SIL204, which demonstrated effective biodistribution and anti-tumor activity against pancreatic cancer metastasis.
Future Plans: The company plans to initiate Phase 2/3 clinical trials for SIL204 in early 2026, with regulatory submissions expected in late 2025 and early 2026, while analysts maintain a Moderate Buy rating with a target price suggesting a potential 436.12% upside.
Silexion Therapeutics Shares Encouraging Preclinical Findings on SIL204's Effectiveness and Distribution in Key Metastatic Sites of Pancreatic Cancer After Systemic Delivery
New Preclinical Data: Silexion Therapeutics announced successful preclinical results showing that their drug SIL204 effectively targets primary and metastatic sites of pancreatic cancer, achieving measurable reductions in tumor burden in a mouse model.
Dual-Route Administration Strategy: The findings support Silexion's dual-route administration approach, combining subcutaneous delivery for metastatic disease with intratumoral delivery for primary tumors, with plans to initiate Phase 2/3 clinical trials in H1 2026.
Silexion Finishes Toxicology Studies for SIL204; Phase 2/3 Trial for Pancreatic Cancer Set to Start in Q2
SIL204 Development: Silexion Therapeutics has completed toxicology studies for SIL204, a next-generation siRNA therapy targeting mutated KRAS oncogenes in pancreatic cancer, showing no systemic organ toxicity.
Therapeutic Potential: SIL204 has demonstrated significant inhibition of cancer cell growth in preclinical models and positive anti-tumor activity in pancreatic cancer, paving the way for regulatory submissions in Israel and Germany.
Clinical Trial Plans: The therapy is set to progress to a Phase 2/3 trial in Q2 2026, utilizing a unique regimen that combines intratumoral and systemic administration to evaluate safety and efficacy in patients with locally advanced pancreatic cancer.
Stock Performance: Silexion's stock has fluctuated between $2.13 and $63.45 over the past year, closing at $2.44, reflecting a 13.48% increase in recent trading.
Silexion Completes Toxicology Studies for SIL204, Plans Phase 2/3 Trial in 2026
- Successful Toxicology Studies: Silexion has completed dual-species toxicology studies for SIL204, confirming no systemic organ toxicity, which lays the groundwork for planned regulatory submissions in Israel and Germany, potentially accelerating clinical trial progress.
- Clinical Trial Timeline: The company is on track to initiate a Phase 2/3 clinical trial for locally advanced pancreatic cancer in Q2 2026, ensuring competitiveness and timely market entry in the oncology sector.
- Innovative Therapy Potential: SIL204, designed as a next-generation RNA interference therapy targeting mutant KRAS oncogenes, has demonstrated significant anti-tumor activity in vitro, indicating its substantial potential in treating aggressive cancers.
- Integrated Treatment Strategy: The company's approach combines both intratumoral and systemic administration, aiming to improve survival rates for patients suffering from high-mortality cancers that currently lack effective treatment options.
Silexion Therapeutics Meets Nasdaq Listing Standards Again
Regaining Compliance: Silexion Therapeutics has regained compliance with Nasdaq listing rules regarding minimum bid price and shareholders' equity, confirming a minimum bid price of $1.00 per share and $2.5 million in shareholders' equity.
Clinical Development Focus: The company is advancing towards Phase 2/3 clinical trials for its RNAi therapy SIL204, which has shown promising preclinical results in inhibiting KRAS-driven cancers, and is committed to developing innovative treatments for solid tumor cancers.
Silexion Therapeutics Stock Rises Following Encouraging Preclinical Results for Pancreatic Cancer
Stock Performance: Silexion Therapeutics Corp. (SLXN) stock rose 14.83% to $5.15 on Thursday, with a trading volume significantly higher than its average, following the release of promising preclinical data.
Preclinical Study Findings: New data shows that SIL204 effectively targets pancreatic cancer metastasis, demonstrating anti-tumor activity and significant reductions in tumor burden across multiple organs in a mouse model, supporting its potential for clinical trials.
What’s Behind the 190% Surge in Silexion Therapeutics Stock (SLXN) Today?
Stock Performance: Silexion Therapeutics (SLXN) stock surged 188.07% in pre-market trading after positive pre-clinical data for SIL204, which demonstrated effective biodistribution and anti-tumor activity against pancreatic cancer metastasis.
Future Plans: The company plans to initiate Phase 2/3 clinical trials for SIL204 in early 2026, with regulatory submissions expected in late 2025 and early 2026, while analysts maintain a Moderate Buy rating with a target price suggesting a potential 436.12% upside.
Silexion Therapeutics Shares Encouraging Preclinical Findings on SIL204's Effectiveness and Distribution in Key Metastatic Sites of Pancreatic Cancer After Systemic Delivery
New Preclinical Data: Silexion Therapeutics announced successful preclinical results showing that their drug SIL204 effectively targets primary and metastatic sites of pancreatic cancer, achieving measurable reductions in tumor burden in a mouse model.
Dual-Route Administration Strategy: The findings support Silexion's dual-route administration approach, combining subcutaneous delivery for metastatic disease with intratumoral delivery for primary tumors, with plans to initiate Phase 2/3 clinical trials in H1 2026.
